SAkuraPEAK: A Phase 1, Multicenter, Open-Label, Uncontrolled Study to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Satralizumab in Adult Patients with AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder with Bodyweight Greater Than 100 Kg (WP44131)

Protocol No
NEURO-GENENTECH-SAKURAPEAK
Phase
I
Summary

This project is being done to assess the pharmacokinetics and pharmacodynamics of satralizumab in patients with NMOSD who weigh more than 100 kg (about 220 pounds).

Description
Satralizumab in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Brain, Spinal Cord, and Nervous System, Multiple Sclerosis